Prospective multi-country registry to characterise eGFR slope in IgAN patients on APRIL inhibition.
Budget vs actual spend
$85k
of $2.1M planned (4%)
Spend is in line with or behind elapsed time. Elapsed: 17%.
Late-by counts days between due date and completion, or due date and today for open milestones.
| Milestone | Due | Completed | Status | Timing | Late by | Evidence |
|---|---|---|---|---|---|---|
| Concept approved | 31 May 2026 | 02 Jun 2026 | Completed | Completed late | 2 d | — |
| Budget review | 31 Jul 2026 | — | Blocked | Overdue | 46 d | Awaiting FY2027 budget confirmation from Finance |
| Contracting | 31 Oct 2026 | — | Not started | Upcoming | — | — |
Insights routed to this initiative.
NICE signals proteinuria alone insufficient; 2-year eGFR slope expected for positive recommendation. Increases urgency…
Access and reimbursement · 14 Aug 2026
Patient advocacy groups prioritise fatigue and prognostic uncertainty over proteinuria; current endpoints perceived as…
Patient experience · 20 Jun 2026
Actions whose result record is this initiative.
No actions reference this initiative as their result.
GLOMERULAR-REG not funded in FY2027, leaving no eGFR slope data for HTA submissions.
P 3 × I 5 = 15 · Budget · Dr. Marcus Lindqvist · due 15 Oct 2026
GLOMERULAR-REG registry depends on FY2027 budget confirmation (Finance) (Cross-functional)
Due 15 Oct 2026 · if delayed: No eGFR data for HTA; access risk in GB/DE
Re-prioritise FY2027 budget to fund GLOMERULAR-REG
Owner Dr. Marcus Lindqvist · approvers Dr. Helen Okafor · needs leadership
Same objective (SO-NPH-02)
Same objective (SO-NPH-02)
Same objective (SO-NPH-02)
| Task | Assignee | Due | Priority | Status |
|---|---|---|---|---|
| Confirm FY2027 budget for GLOMERULAR-REG | MLDr. Marcus Lindqvist | 05 Sept 2026 | Critical | Blocked |
No audit events for this record
Audit events are written when the record is created, changed, approved, signed or exported.
Data lineage